Drug Profile
Gunagratinib - InnoCare Pharma
Alternative Names: ICP-192Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator InnoCare Pharma
- Class Amides; Antineoplastics; Ethers; Ketones; Methylamines; Pyrazoles; Pyrrolidines; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Cholangiocarcinoma
- Phase II Bladder cancer; Solid tumours; Urogenital cancer
- Phase I/II Head and neck cancer
- No development reported Gastric cancer; Liver cancer
Most Recent Events
- 12 Apr 2024 Chemical structure information added
- 28 Mar 2024 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease, Second-line therapy or greater) in China
- 28 Mar 2024 No recent reports of development identified for research development in Liver-cancer in China